Articles related to CHECKPOINT INHIBITORS

Reed-Sternberg cells harbor chromosome 9p24 amplification encoding PD-1 ligand, creating therapeutic vulnerability exploited by checkpoint inhibitors with remarkable clinical responses.

In mice whose immune cells that lack the ability to recognize flagellin, immune therapy induced long-term control of ovarian tumor growth in almost 80% of animals.

Pembrolizumab now represents a transformative advancement in the adjuvant treatment of clear cell renal cell carcinoma, significantly reducing the risk of progression or death by 38% compared to placebo.

The ESMO Congress 2023 has highlighted how international studies in NSCLC are currently being reported at a rapid pace. This underscores the importance of staying updated on these advancements to provide optimal patient care.

Discover how a novel combination therapy targeting EGFR and AXL proteins could revolutionize the treatment of head and neck squamous cell carcinoma and lung adenocarcinoma.

The FDA’s recent approval of Akeega, a combination therapy for BRCA-mutated mCRPC, marks a significant advancement in targeted treatment. This approval, based on the MAGNITUDE study, offers a new therapeutic option for patients, supported by robust clinical data.